Clinical trial

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

NCT07811232

Study summary

ClinicalTrials.gov

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention AL58805 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AL8326 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Eribulin Normalized identity: eribulin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrant View linked drug · Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE1 / PHASE2

Conditions

Endometrial Neoplasmsunresolved

Soft Tissue Sarcoma (STS)unresolved

Breast Neoplasmsunresolved

Interventions

AL58805DRUG

AL8326DRUG

EribulinDRUG · verified · RxNorm: eribulin

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

Advenchen Pharmaceuticals, LLC.lead sponsor

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07811232 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.